AI Article Synopsis
- The study found high levels of the protein annexin A1 (ANXA1) in urine from a mouse model and patients with various glomerular diseases.
- ANXA1 was detectable in most patients except those with minimal change disease (MCD) and was associated with kidney damage severity.
- The research suggests that ANXA1 could serve as a key biomarker for early diagnosis and monitoring of glomerular injuries, helping to distinguish MCD from other kidney disorders.
Article Abstract
Background: We recently demonstrated high urine levels of annexin A1 (ANXA1) protein in a mouse Adriamycin-induced glomerulopathy (ADG) model.
Objective: To establish ANXA1 as a potential biomarker for glomerular injury in patients.
Methods: A time-course study in the mouse ADG model, followed by renal tissues and urine samples from patients with various types of glomerular disorders for ANXA1.
Results: Urinary ANXA1 protein was (1) detectable in both the ADG model and in patients except those with minimal change disease (MCD); (2) positively correlated with renal lesions in patients; and (3) early detectable in diabetes patients with normoalbuminuria.
Conclusions: ANXA1 is a universal biomarker that is helpful in the early diagnosis, prognostic prediction, and outcome monitoring of glomerular injury. Measurement of urinary ANXA1 protein levels can help in differentiating MCD from other types of glomerular disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925619 | PMC |
| http://dx.doi.org/10.1155/2014/854163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!